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The prevalence of depression, anxiety, 
and stress in patients with breast 
cancer in Southeast Iran in 2019: 
a cross-sectional study
ABSTRACT
Introduction. Today, breast cancer patients suffer from various psychological symptoms that impose irreversible 
effects on their quality of life. The aim of the present study was to determine the prevalence of depression, anxiety, 
and stress in patients with breast cancer.
Material and methods. This descriptive study was performed on 190 women with breast cancer from January 
1, 2019 to July 30, 2019. Data collection was carried out using a convenience sampling method. The Standard 
Depression, Anxiety, and Stress Scale (DASS-21) was used to assess depression, anxiety, and stress.
Results. The mean age of the patients was 46.3 years. Results showed the prevalence of depression, anxiety, 
and stress to be 28.4%, 43.2%, and 14.7%, respectively. 
Conclusion. The results indicate that it is vital to measure the level of depression and anxiety in women with 
breast cancer, which are two common mental disorders in breast cancer.
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Introduction
Breast cancer is considered one of the most impor-
tant and most common cancers in women today. Breast 
cancer caused more than 375,900 deaths in 2017 [1]. 
Breast cancer also imposes costs of $88 billion a year to 
patients with breast cancer [2]. Breast cancer diagnosis 
is one of the most stressful medical situations in a per-
son’s life [3]. Breast cancer can have a profound effect 
on the patient’s physical, mental, and social status and 
overall well-being [4]. Psychosocial interventions can 
improve the quality of life (symptoms of depression and 
anxiety) in both groups of women with breast cancer 
[5]. Depression and anxiety have negative effects on 
the quality of life of cancer patients, and in this regard, 
the Hospital Anxiety and Depression Scale (HADS) is 
currently a useful method to screen for these problems 
[6, 7]. Studies show that 10–50% of cancer patients suffer 
from psychosocial disorder (depression, anxiety, despair, 
social isolation, and work and financial problems), and 
the above figure increases in last stages of cancer [8, 9]. 
A recent meta-analysis shows that the global prevalence 
of depression among breast cancer patients is 32.2% 
[10]. Depression is a very common disorder in all ages 
and races, as well as in men and women worldwide 
[11]. Depression has a negative effect on quality of 
life, length of stay, and treatment outcome of cancer 
patients [12]. Another common disorder among cancer 
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patients is anxiety, the prevalence of anxiety is 41.9% 
[13]. Anxiety is associated with cancer, and these psycho-
logical symptoms are the most common psychological 
symptoms found in cancer patients. Patients with inef-
fective coping strategies exhibit higher levels of anxiety 
and depression, and social support led to a significant 
decrease in the level of anxiety and depression [14, 15]. 
Stress or perceived stress was also expressed as another 
psychological factor in cancer patients and was strongly 
related with depression [16]. Determining the exact level 
of depression and anxiety can help policymakers and 
healthcare providers plan for better control of these 
diseases. The aim of the present study was to determine 
the prevalence of depression, anxiety, and stress among 
patients with breast cancer.
Methods
Design
This cross-sectional study was performed on 
190 women with breast cancer stages 3–4 referred 
to oncology wards of three educational hospitals in 
three Iranian cities (Zahedan, Arak, and Mashhad) 
from 1 January 2019 to 30 July 2019. Patients were 
selected through convenience sampling. Inclusion 
criteria included patients aged above 18 years, with no 
systemic disease.
Instruments
The standard depression, anxiety, and stress scale 
— 21 items (DASS-21) was used to assess depression, 
anxiety, and stress in patients [17]. This instrument con-
sisted of 21 items, with seven items for each subscale. 
The instrument was scored based on a four-point Likert 
scale ranging from of 0 to 3 (never, rarely, sometimes, 
and always). Depression levels were categorised into 
four categories, which indicated normal (score: 0–9), 
low (score: 10–13), moderate (score: 14–20), and severe 
(28 and above) level of depression. Normal, low, mode-
rate, severe, and very severe anxiety were also indicated 
by scores of 0–7, 8–9, 10–14, 15–19, and 20 and above, 
respectively. The validity and reliability of this instru-
ment has been confirmed in various Iranian [18, 19] and 
international (non-Iranian) [20, 21] populations. The 
demographic characteristics studied included age, city 
of residence, level of education, and marital status.
Data collection
Data collection was carried out after making co-
ordination with the hospital cancer department and 
explaining the study objectives to the patients in simple 
language. Questionnaires were then distributed among 
the qualified patients who expressed their consent to 
participate in the study. Patients were given 15 min-
utes to complete the questionnaires. Questionnaires 
were completed by the researcher in the case of illiter-
ate participants.
Ethical considerations
The present study was approved by the Ethics 
Committee of Zahedan University of Medical Sciences 
(Ethic code: IR.ZAUMS.REC.1392.5962). Written and 
oral consent was obtained from all participants, and 
they were assured that their information would be kept 
confidential. The STROBE checklist was also used to 
report the study [22].
Statistical analysis
Descriptive statistical tests (mean, standard devia-
tion, frequency, and percentage) were used to describe 
demographic characteristics of the participants and ana-
lytical tests (chi-square) were also used to examine the 
relationship between demographic characteristics with 
stress, anxiety, and depression. SPSS Version 18.0 for 
Windows (SPSS Inc., Chicago, IL, USA) was used to 
analyse the data. Confidence interval of 95% and a sig-
nificance level of P < 0.05 was considered significant. 
Results
All 190 patients with breast cancer were evaluated 
(response rate = 100%). The mean age of patients was 
46.3 years (range: 19–76 years). The majority of the 
participants lived in Zahedan (77.9%), had high school 
education (25.3%), and were married (84.2%) (Table 1).
The prevalence of mild, moderate, and severe 
depression was 18.4%, 9.5%, and 0.5%, respectively. 
The prevalence of anxiety was 43.2%. The average 
prevalence of stress was 14.7%, with 12.6%, 1.6%, and 
0.5%, for mild, moderate, and severe stress, respectively 
(Table 2). 
Discussion
The present study investigated the prevalence of 
psychological factors (depression, anxiety, and stress) in 
breast cancer patients and revealed that 28.4%, 43.2%, 
and 14.7% of patients suffered from depression, anxiety, 
and stress, respectively.
Approximately one-third (28.4%) of patients suffered 
from depression, which is similar to the global prevalence 
of depression (32.2%) and to results from studies car-
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ried out by Montazeri et al. (29.4%) [23], Taghavi et al. 
(34.2%) [24], and Nikbakhsh et al. (27.5%) [25] in differ-
ent parts of Iran. The above figure was, however, lower 
than the rate reported in studies by Ramezani et al. [26] 
and Mashhadi et al. [27]. This difference could be due 
to differences in participants’ place of residence, demo-
graphic characteristics of participants, methodological 
differences of the studies, and sample size.
High levels of mental distress for sustained periods of 
time in cancer patients may lead to anxiety, depression, 
or both [28]. The mortality rate is higher in depressed 
cancer patients than non-depressed patients [6]. De-
pression is very common in breast cancer patients; the 
prevalence of depression is 47.4% [10, 29], which can 
significantly affect the quality of life of patients [30]. Ac-
cording to various studies, the prevalence of depression 
in cancer patients ranges from 16–67% [31–33].
The prevalence of anxiety in the present study was 
43.2%, which was close to the global prevalence of 
anxiety (41.9%) [13] and lower than the figure reported 
in the study by Ashbury (77%) [13]. Anxiety had a sig-
nificant effect on the feeling of breast cancer patients 
and their coping mechanisms [34]. Results of a study 
showed that 16% of women with breast cancer were 
diagnosed as depressed until 6 to 13 years after treat-
ment [35]. Other studies have shown that the prevalence 
of depression in cancer patients is estimated to be 
15–30% or higher [(36–38], and although anxiety and 
depression are commonly seen in breast cancer patients, 
exacerbate the symptoms of the disease, and lead to 
no response to treatment, these mental disorders are 
ignored and left untreated [39]. Achieving understand-
ing of these common mental disorders and related psy-
chosocial factors can help plan treatment and may lead 
to more successful treatment [40]. Lueboonthavatchai 
concluded that the prevalence of anxiety disorder and 
anxiety symptoms was 16% and 19%, respectively [41].
Theoretically, stress is defined as the body’s response 
to environmental or mental conflicts, or as the internal 
response that depends on their ability to cope with 
environmental stress [42]. In a meta-analysis, research-
ers concluded that stressful events are not associated 
with the risk of breast cancer in women [43]; however, 
high-intensity stress may be a potential risk factor for 
breast cancer. A study by Nikbakhsh et al. on 150 cancer 
patients in Iran showed that 44 participants (29.3%) had 
mild anxiety and 25 (16.7%) had symptomatic anxiety 
and mild depression, which is inconsistent with the pre-
sent study, which showed lower stress rates [25]. This 
diffe rence could be due to the type of cancer being stud-
ied and methodological differences. The main strength 
Table 1. Participants demographic characteristics of breast 
cancer patients (n = 190) 
Variables N (%) 
Mean ± SD
Age (years) 46.3 ± 12.2
City of residence
    Zahedan
    Mashhad 
    Arak
148 (77.9)
23 (12.1)
19 (10)
Education level
    Illiterate
    Elementary
    Secondary
    High school
    University graduate
39 (20.5)
45 (23.7)
23 (12.1)
48 (25.3)
35 (18.4)
Marital status  
    Single 
    Married
    Widow
16 (8.4)
160 (84.2)
14 (7.4)
Table 2. Prevalence of depression, anxiety, and stress among breast cancer patients
Variables N (%) Mean ± SD Range
Depression
    Normal
    Low
    Moderate
    Severe
136 (71.6)
35 (18.4)
18 (9.5)
1 (0.5)
6.7 ± 4.9 0–21
Anxiety
    Normal
    Low
    Moderate
    Severe
108 (56.8)
26 (13.7)
50 (26.3)
6 (3.2)
6.7 ± 4.3 0–18
Stress
    Normal
    Low
    Moderate
    Severe
162 (85.3)
24 (12.6)
3 (1.6)
1 (0.5)
8.9 ± 5.1 37–160
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of the present study was the investigation of depression, 
anxiety, and stress concurrently. Another strength of the 
present study was that participants from different cities 
with different cultures were included, especially from 
areas where fewer studies had previously been carried 
out. The main limitations of the present study were as 
follows: 1. The sample size was low, which could limit 
the generalisation of results. 2. This is a descriptive study 
that should consider the specific limitations of these 
studies when interpreting the study results. 3. Variables 
were evaluated using self-report measures instead of 
non-clinical evaluation, which should thus be taken 
into consideration.
Conclusions
Results showed that approximately one-third of 
patients suffer from depression and about half of them 
from anxiety. The high prevalence of depression and 
anxiety indicates the importance of timely and periodic 
evaluation of psychological symptoms in patients with 
breast cancer.
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